Brief: Scope Fluidics Unit Signs Deal To Conduct Clinical Trials For FDA Certification
25/06/2025 12:28
June 25 (Reuters) - Scope Fluidics SA SCPP.WA: UNIT BACTEROMIC SINGS AGREEMENT TO CONDUCT CLINICAL TRIALS FOR FDA CERTIFICATION ESTIMATED COST OF STUDIES ABOUT $2 MILLION AIMS FOR FDA CERTIFICATION OF BACTEROMIC SYSTEM IN 2027 Source text: nEM92C7wVa Further company coverage: SCPP.WA (Reporting by Gdańsk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Scope Fluidics SA
See all newsBrief: Scope Fluidics' EDOCERA Project Meets Second Goal Of Developing Prototype Of Device For Detecting Stroke Symptoms
Brief: Scope Fluidics Q2 Net Loss At 10.1 Million Zlotys
Brief: Scope Fluidics Unit Signs Deal With Poland's PARP For Up To 14.4 Mln Zlotys In Funding For HYBOLIC Project
Brief: Scope Fluidics Says FDA Certification For UNI FAST Panel Planned For Second Half Of 2027
Brief: Scope Fluidics Extends Deadline For First Goal In Hybolic Project